


DHFR-IN-17

Cat. No.:	HY-162358
Molecular Formula:	C ₁₇ H ₂₁ IN ₄ O ₂
Molecular Weight:	440.28
Target:	Bacterial; Dihydrofolate reductase (DHFR)
Pathway:	Anti-infection; Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	DHFR-IN-17 (compound j9) is an oral active SaDHFR inhibitor with the IC ₅₀ of 0.97 nM. DHFR-IN-17 shows antibacterial activity against <i>S. aureus</i> with the minimum inhibitory concentration of 0.031 µg/mL ^[1] .	
In Vivo	DHFR-IN-17 (compound j9) (205 and 10mg/kg, oral gavage for 3 consecutive days) alleviates the skin infection damage in MRSA-induced epidermal infections in C57 mice ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	MRSA-induced epidermal infections in C57 mice ^[1]
	Dosage:	205 and 10mg/kg
	Administration:	Oral gavage for 3 consecutive days
	Result:	Alleviates the skin infection damage.

REFERENCES

[1]. Huang Z, et al. Design, Synthesis, and Biological Evaluation of 5-(5-Iodo-2-isopropyl-4-methoxyphenoxy)pyrimidine-2,4-diamine (AF-353) Derivatives as Novel DHFR Inhibitors against *Staphylococcus aureus*. *J Med Chem*. Published online March 11, 2024.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA